In the KRAS oncogenic mutation and p53 loss of function mutation (KP) conditional knock-in mouse model of non-small cell lung cancer (NSCLC), tumors co-evolve naturally with host’s immune system in a clinically relevant TME is used by the Riddell group to explore the strategy to overcome resistance of CAR-T cell therapy. This evidence concerns the gene TP53 and non-small cell lung carcinoma.